PMID- 32163901 OWN - NLM STAT- MEDLINE DCOM- 20200625 LR - 20200625 IS - 1873-376X (Electronic) IS - 1570-0232 (Linking) VI - 1142 DP - 2020 Apr 1 TI - A novel insight into the potential toxicity mechanisms of Zhi-Zi-Hou-Po decoction by dynamic urinary metabolomics based on UHPLC-Q-Exactive Orbitrap-MS. PG - 122019 LID - S1570-0232(19)31341-8 [pii] LID - 10.1016/j.jchromb.2020.122019 [doi] AB - In recent years, depression occurs frequently. Given the long duration of the disease and the high risk of recurrence, the treatment of depression requires long-term medication. Zhi-Zi-Hou-Po Decoction (ZZHPD) has been used in clinical treatment of depression and related diseases for many years, and the potential toxic damage caused by its long-term use has gradually emerged. Existing research methods that expose toxicity by a one-time administration of large doses cannot provide a reference for clinical safe drug use. In this study, the potential toxicity of ZZHPD in repeated administration was studied by urinary metabolomics with nondestructive sampling. Based on ultra-high performance liquid chromatography-quadruple-Exactive Orbitrap mass spectrometry (UHPLC-Q-Exactive Orbitrap-MS) and chemometrics, 33 differential biomarkers, such as 3-hydroxybutyric acid, indole sulfuric acid, hippuric acid and citric acid, were screened and dynamically tracked. The changes of some endogenous substances showed obvious time dependence. Further analysis of these time-dependent components in combination with network pharmacology revealed that the potential hepatotoxicity and nephrotoxicity of ZZHPD were related to the disorders of amino acid metabolism, energy metabolism, lipid metabolism, nucleotide metabolism and gut microflora metabolism pathway. This study can better grasp the occurrence and development of drug toxicity, and provide reference for rational and safe drug use and potential toxicity prevention of ZZHPD. CI - Copyright (c) 2020. Published by Elsevier B.V. FAU - Zhang, Qianqian AU - Zhang Q AD - Key Laboratory of Drug Quality Control and Pharmacovigilance (China Pharmaceutical University), Ministry of Education, Nanjing 210009, China; Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing 210009, China. Electronic address: qianqianzhang618@163.com. FAU - Feng, Fang AU - Feng F AD - Key Laboratory of Drug Quality Control and Pharmacovigilance (China Pharmaceutical University), Ministry of Education, Nanjing 210009, China; Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing 210009, China. Electronic address: fengfang1@hotmail.com. LA - eng PT - Journal Article DEP - 20200203 PL - Netherlands TA - J Chromatogr B Analyt Technol Biomed Life Sci JT - Journal of chromatography. B, Analytical technologies in the biomedical and life sciences JID - 101139554 RN - 0 (Antidepressive Agents) RN - 0 (Biomarkers) RN - 0 (Drugs, Chinese Herbal) RN - 0 (Iridoids) RN - 0 (Zhi-Zi-Hou-Pu decoction) SB - IM MH - Animals MH - Antidepressive Agents/adverse effects/*pharmacokinetics/urine MH - Biomarkers/urine MH - Chromatography, High Pressure Liquid MH - Drugs, Chinese Herbal/adverse effects/*pharmacokinetics MH - Iridoids/adverse effects/*pharmacokinetics/urine MH - Male MH - Metabolomics MH - Rats, Sprague-Dawley MH - Signal Transduction MH - Tandem Mass Spectrometry OTO - NOTNLM OT - Dynamic OT - Potential toxicity OT - UHPLC-Q-Exactive Orbitrap-MS OT - Urinary metabolomics OT - Zhi-Zi-Hou-Po decoction COIS- Declaration of Competing Interest The authors declare that there are no conflicts of interest in relation to this work. EDAT- 2020/03/13 06:00 MHDA- 2020/06/26 06:00 CRDT- 2020/03/13 06:00 PHST- 2019/09/07 00:00 [received] PHST- 2019/12/09 00:00 [revised] PHST- 2020/02/02 00:00 [accepted] PHST- 2020/03/13 06:00 [pubmed] PHST- 2020/06/26 06:00 [medline] PHST- 2020/03/13 06:00 [entrez] AID - S1570-0232(19)31341-8 [pii] AID - 10.1016/j.jchromb.2020.122019 [doi] PST - ppublish SO - J Chromatogr B Analyt Technol Biomed Life Sci. 2020 Apr 1;1142:122019. doi: 10.1016/j.jchromb.2020.122019. Epub 2020 Feb 3.